Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients

BACKGROUND AND OBJECTIVES: A clinical trial was conducted to measure and analyse the pharmacokinetic parameters of a lipid formulation of risperidone, VAL401. The VAL401 formulation is designed to repurpose risperidone from an antipsychotic to an adenocarcinoma treatment, with the lipid formulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Dilly, Suzanne J., Morris, George S., Taylor, Paul C., Parmentier, Frederic, Williams, Coralie, Afshar, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616216/
https://www.ncbi.nlm.nih.gov/pubmed/30628010
http://dx.doi.org/10.1007/s13318-018-00538-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616216/
https://www.ncbi.nlm.nih.gov/pubmed/30628010
http://dx.doi.org/10.1007/s13318-018-00538-4

Ejemplares similares